A human study to evaluate the effect and the safety of GUCO on blood triglyceride levels

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003872

Enrollment

100

Registered

2019-04-30

Start date

2018-07-31

Completion date

Unknown

Last updated

2021-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : After the 2-week run-in period, enrolled subjects will be randomly assigned to treatment or placebo groups at visit 2 (week 0). The subjects will be asked to consume 4 capsules a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agree to participate and signs informed consent form 2) Men and women over 20 years old (ratio of men and women 1:1) 3) 150 mg/dL =Blood triglyceride levels <200 mg/dL

Exclusion criteria

Exclusion criteria: 1) Excessive exercise (= 10 hours/week) 2) Heavy smoking (= 20 cigarettes/day) 3) Alcoholism or alcohol consumption more than 420g/week (soju 7 bottles/week) 4) BMI (Body Mass Index) 36 6) Following diseases : hyperlipidemia, diabetes, hypertension, liver disease, intestinal disease(inflammatory disease, lactose intolerance, etc), renal disease, cardiovascular disease, cerebrovascular disease, pancreatitis, cancer, thyroid disease, dementia, Parkinson's disease, depression, anorexia/bulimia, multiple sclerosis, spine injury, hypokalemia, uerine disease, etc. 7) Following medicines within 1 month before the first visit or during study, : lipid-lowering agents(ursodeoxycholic acid), statin, etc), blood glucose-lowering drugs, antibiotics, drugs on intestine function, hormones, oral contraceptives, appetite depressants/stimulant, diuretics, beta-blockers, contraceptives, steroids, tricyclic antidepressants, laxatives, antidepressants, et al. But subjects taking thiazide or beta-blockers with no dose change for 1 year and during study can be enrolled. 8) Continuous consumption of oriental herbal medicine within 1 month before the first visit 9) Continuous consumption of dietary supplements with efficacy on blood lipids, blood glucose, body fat metabolism within 1 month before the first visit (phytosterol, omega-3 fatty acids, psyllium husk, aloe, chitosan, onion extract, nondigestible maltodextrin, dietary fiber, etc) 10) Subjects with hypersensitivity to test materials 11) Participation in other human study within one month before the first visit 12) Pregnant or lactating women 13) Any condition that the principal investigator believes may put the subjects at undue risk

Design outcomes

Primary

Measure	Time frame
Blood triglyceride	—

Secondary

Measure	Time frame
Total cholesterol, LDL-C, HDL-C, VLDL-C;Apo B100, Apo CII, fasting blood glucose, insulin;Anthropometric measurements;0, 12?	—

Countries

Korea, Republic of

Contacts

Public ContactJonghan Lim

Inha University

ekeeper21@naver.com+82-32-890-2861

Outcome results